These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6610534)

  • 1. Hypotensive reaction after infusion of a perfluorochemical emulsion.
    Waxman K; Cheung CK; Mason GR
    Crit Care Med; 1984 Jul; 12(7):609-10. PubMed ID: 6610534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss.
    Police AM; Waxman K; Tominaga G
    Crit Care Med; 1985 Feb; 13(2):96-8. PubMed ID: 3967511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfluorochemical emulsion oxygen transport fluids: a clinical review.
    Tremper KK; Anderson ST
    Annu Rev Med; 1985; 36():309-13. PubMed ID: 3888055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.
    Teicher BA; Lazo JS; Merrill WW; Filderman AE; Rose CM
    Cancer Chemother Pharmacol; 1986; 18(3):213-8. PubMed ID: 2433068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation.
    Moulder JE; Fish BL
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1193-6. PubMed ID: 3141322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a perfluorochemical emulsion on the rat hepatic mixed function oxidase system.
    Ravis WR; Ramakanth S; Brzozowski DM; Hamrick ME
    J Pharm Pharmacol; 1992 Mar; 44(3):219-23. PubMed ID: 1354727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma-mediated alterations of erythrocyte deformability by perfluorochemical blood substitutes.
    Holloway GM; O'Rear EA; Fung BM
    Blood; 1986 Jan; 67(1):173-6. PubMed ID: 3940545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA.
    Nishimura N; Sugi T
    Crit Care Med; 1984 Jan; 12(1):36-8. PubMed ID: 6690204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA.
    Teicher BA; Rose CM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1311-3. PubMed ID: 3093415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a blood substitute (Fluosol-DA, 20%) on cerebral ischemia.
    Oda Y; Handa H; Nagasawa S; Naruo Y; Asato R; Yonekawa Y
    Neurol Res; 1982; 4(1-2):35-45. PubMed ID: 6127644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluosol DA and oxygen as an adjuvant to the radiotherapeutic management of advanced head/neck carcinoma.
    Lustig RA; Rose CM; McIntosh-Lowe NL
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):511-8. PubMed ID: 3179488
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.
    Kim GE; Song CW
    Cancer Chemother Pharmacol; 1989; 25(2):99-102. PubMed ID: 2513138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.
    Mitsuno T; Ohyanagi H; Naito R
    Ann Surg; 1982 Jan; 195(1):60-9. PubMed ID: 7034658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of fetal exchange transfusion with a red blood cell substitute.
    Ambrose A; Cefalo RC; Bowes WA
    Am J Obstet Gynecol; 1986 Mar; 154(3):667-74. PubMed ID: 3082209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis.
    Vercellotti GM; Hammerschmidt DE; Craddock PR; Jacob HS
    Blood; 1982 Jun; 59(6):1299-1304. PubMed ID: 7082830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of fluorocarbon emulsions in cancer radiotherapy.
    Guichard M
    Radiother Oncol; 1991; 20 Suppl 1():59-64. PubMed ID: 2020771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenously infused Fluosol-DA 20% in rats.
    West L; McIntosh N; Gendler S; Seymour C; Wisdom C
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1319-23. PubMed ID: 3759552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%.
    Tremper KK; Vercellotti GM; Hammerschmidt DE
    Crit Care Med; 1984 May; 12(5):428-31. PubMed ID: 6713912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in human cultured cells exposed to a perfluorocarbon emulsion.
    Wake EJ; Studzinski GP; Bhandal A
    Transfusion; 1985; 25(1):73-7. PubMed ID: 2982223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with Fluosol-DA (20%) in the United States.
    Tremper KK; Levine EM; Waxman K
    Int Anesthesiol Clin; 1985; 23(1):185-97. PubMed ID: 3884514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.